Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease - 07/02/19

| This work was supported by the National Institutes of Health (grants K23HL111113, K23AI118804, R01HL128241, U19 AI095219, and T32AI007306-32), and by generous contributions from the Kaye and Vinik families. |
|
| Disclosure of potential conflict of interest: K. N. Cahill has served on scientific advisory boards for Teva, Regeneron, and Optinose. E. Israel has received consultancy fees from AstraZeneca, Philips Respironics, Regeneron Pharmaceuticals, Birk Rock Bio, Nuvelution Pharmaceuticals, Vitaeris Inc, Sanofi, and Merck. T. M. Laidlaw has served on scientific advisory boards for GlaxoSmithKline and Sanofi-Genzyme. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 143 - N° 2
P. 799 - février 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
